Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$13.84 -0.54 (-3.76%)
As of: Sep 4, 2026 · 3:59 PM EDT

Monte Rosa Therapeutics (GLUE) Profit After Tax (QoQ) (2020 - 2026)

Analysis

Monte Rosa Therapeutics (GLUE) Profit After Tax (QoQ) (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Monte Rosa Therapeutics 1.40 Bn 771.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.54%
Mar 31, 2026 3.71%
Dec 31, 2025 -70.67%
Sep 30, 2025 -119.47%
Jun 30, 2025 -126.32%
Mar 31, 2025 266.15%
Dec 31, 2024 153.67%
Sep 30, 2024 21.28%
Jun 30, 2024 5.19%
Mar 31, 2024 6.59%
Dec 31, 2023 1.89%
Sep 30, 2023 0.84%
Jun 30, 2023 -9.80%
Mar 31, 2023 -6.08%
Dec 31, 2022 -9.97%
Sep 30, 2022 -3.75%
Jun 30, 2022 -10.60%
Mar 31, 2022 -5.95%
Dec 31, 2021 -10.88%
Sep 30, 2021 -10.69%